Big pharma, M&A, Pharma

Otsuka M&A deals Astex in $886 million acquisition

Posted on 05 September 2013

Tags: , , ,

Japanese drugmaker Otsuka Holdings has entered M&A deals to buy Astex Pharmaceuticals for about $886 million.

The big pharma company aims to tap cancer drugs under development by the U.S. biotechnology company with the M&A deals.

The M&A deals come as Otsuka seeks to increase revenue streams as patents for its mainstay Abilify schizophrenia treatment will begin to expire.

Cancer is attracting increased investment from biotech and pharmaceutical companies as a series of breakthroughs in understanding the genetic basis of the disease fuels a run of promising new medicines.

Astex, whose only approved drug, Dacogen, treats a blood disorder called myelodysplastic syndromes, is developing drugs to treat leukemia, prostate, lung and ovarian cancer.

The biotech company said last month that SGI-110, an experimental drug for acute myeloid leukemia, produced positive results in a Phase II mid-stage clinical trial.


Report: Ovarian Cancer Partnering

Report: Lung Cancer Partnering

Report: Leukemia Partnering

Report: Oncology Partnering Terms and Agreements

Report: Partnering Deals and Alliances with Otsuka

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply